Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358814 | 1.00 | SMN1; SMN2 (0.33) | SMN1; SMN2HSD11B1 | |
| SCHEMBL27217059 | 0.87 | POLB (0.33) | SMN1; SMN2HSD11B1 | |
| SCHEMBL27217064 | 0.87 | POLB (0.33) | SMN1; SMN2HSD11B1 | |
| SCHEMBL27217183 | 0.80 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL1550841 | 0.78 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL2286807 | 0.78 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL2285251 | 0.74 | DPP4 (0.36) | SMN1; SMN2 | |
| SCHEMBL1550843 | 0.74 | DPP4 (0.36) | SMN1; SMN2 | |
| SCHEMBL2286812 | 0.74 | DPP4 (0.36) | SMN1; SMN2 | |
| SCHEMBL27217303 | 0.72 | SMN1; SMN2 (0.31) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569314-B1 | FUSED BICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICALS LLC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-09-26 | — | — | US | disclosed |
| US-8445510-B2 | Fused bicyclic kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | ALK, RET, MET | SMN1; SMN2 1756/4885HSD11B1 2061/4885 |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | ALK, RET, MET | SMN1; SMN2 1756/4885HSD11B1 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.